RESULTS: Our cohort consisted of 38 patients (24 male, 14 female), with a median age of 64 years (44-85), and a median BMI of 34.1 kg/m2 (22.3-59.3). The MM was characterized using the International Staging System (ISS) with Stage I (55%), Stage II (37%), and Stage III (8%). Amyloidosis was seen in 4 patients. Primary reason for referral was clinical suspicion of SDB (97%). Of note, 25 (68%) patients were taking narcotic pain medication, and 11(30%) were taking a sleep aide at the time of PSG. Excessive daytime sleepiness and sleep disturbance were present as measured by an elevated median Epworth Sleepiness Scale score, 11 (5-21) and an elevated median Pittsburgh Sleep Quality Index score, 8 (2-16), respectively. Echocardiogram was available on 30 patients and revealed: valvular dysfunction (70%), diastolic dysfunction (41%), left ventricular hypertrophy (37%), and cardiomyopathy (7%). PSG data revealed a median total sleep time of 406 minutes (210-502.5). The median time spent in N1=12% (1-45), N2=68% (50-91), N3=0% (0-34), and REM=14% (0-31). The median AHI was 13 (1-74), and the median Sa02 nadir was 82.5% (56-93). SDB was diagnosed in 95% of patients with obstructive sleep apnea (83%) being the predominate diagnosis. The distribution of the severity of OSA was mild (37%), moderate (36%) and severe (27%). Central sleep apnea (CSA) was diagnosed in 14% of patients, and sleep-related hypoventilation in 3% of patients. Of the patients diagnosed with SDB, 86% were prescribed positive pressure therapy, and 58% were compliant at the time of follow up.